|
Characteristic
|
Finding
|
Range (min-max)
|
|---|
|
Age (years)
|
57 +/− 15
|
20–83
|
|
Female gender, n (%)
|
40 (80)
| |
|
Height (m)
|
1.63 (1.56–1.73)
|
1.46–1.95
|
|
Weight (kg)
|
71 +/− 16
|
40–105
|
|
BSA (m2)
|
1.8 +/− 0.2
|
1.4–2.4
|
|
6MWD (metres)
|
333 (150–440)
|
0–582
|
|
NT-proBNP (ng/L)
|
320 (110–841)
|
50–52,746
|
|
WHO FC, n (%)
|
|
1
|
2 (4)
| |
|
2
|
12 (24)
| |
|
3
|
32 (64)
| |
|
4
|
4 (8)
| |
|
PAH, n (%)
|
39 (78)
| |
|
Group 1
|
33 (66)
| |
|
- Idiopathic
|
8
| |
|
- CTD
|
23
| |
|
- PVOD
|
1
| |
|
- Portopulmonary
|
1
| |
|
Group 2
|
2 (4)
| |
|
Group 3
|
2 (4)
| |
|
Group 4
|
1 (2)
| |
|
Group 5
|
1 (2)
| |
|
PAH therapy, n (%)
|
|
- Phosphodiesterase type 5 inhibitor
|
24 (48)
| |
|
- Endothelin receptor antagonist
|
23 (46)
| |
|
- Intravenous Epoprostenol
|
2 (4)
| |
- All normally distributed data are presented as mean ± standard deviation, non-parametric data are presented as median (Q1-Q3) and proportions as n (%)
- BSA Body surface area, CTD Connective tissue disease, NT-proBNP N-terminal pro-brain natriuretic peptide, PAH Pulmonary artery hypertension, PVOD Pulmonary veno-occlusive disease, WHO FC World Health Organisation Functional Class, 6MWD 6-min walk distance
